Home・Listă Acțiuni・Royalty Pharma PLC (Class A)

Royalty Pharma PLC (Class A)

Închisă

SectorSănătate

59.83 0.98

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

58.04

Maxim

59.45

Indicatori cheie
By Trading Economics
Venit	-589M -295M
Vânzări	44M 674M
P/E Medie Sector	30.511 57.002
EPS	1.32
Randament dividend	1.6
Marjă de profit	-43.713
Angajați	100
EBITDA	-387M 176M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+12.06% upside

Dividende
By Acuity
Randament dividend Medie Sector	1.60% 2.22%
Următoarele câștiguri	4 nov. 2026
Data viitoare de dividende	10 sept. 2026
Următoarea dată ex-dividende	13 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	577M 33B
Deschiderea anterioară	58.85
Închiderea anterioară	59.83

Sentimentul știrilor

By Acuity

81%

19%

321 / 340 Clasament în Healthcare

Royalty Pharma PLC (Class A) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 aug. 2026, 19:36 UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

15 aug. 2026, 00:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

14 aug. 2026, 19:46 UTC

Event

Social Media

Royalty Pharma PLC declared a $0.235 per share dividend today, with shares advancing since Thursday's close and near the upper end of their one-month range.

13 aug. 2026, 20:02 UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

12 aug. 2026, 20:01 UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

11 aug. 2026, 19:56 UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

10 aug. 2026, 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting notable strength and unusual activity since Monday's close, with no specific news identified.

7 aug. 2026, 23:41 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

6 aug. 2026, 23:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

5 aug. 2026, 19:31 UTC

News

Royalty Pharma PLC raised its full-year guidance for Portfolio Receipts to $3.4 billion to $3.5 billion, contributing to a higher trading session.

4 aug. 2026, 19:26 UTC

Royalty Pharma PLC shares are higher today, rebounding after earlier pulling back from a session high. The stock has fluctuated within a routine range.

3 aug. 2026, 23:46 UTC

Royalty Pharma PLC shares are near unchanged in after-market trading, reflecting minimal movement since Monday's close and remaining below the 20-day moving average.

1 aug. 2026, 00:03 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline over the past four sessions. No specific news was identified to explain the move.

31 iul. 2026, 23:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting broader market trends despite some gains in mega-cap stocks. The stock remains below its 20-day moving average.

30 iul. 2026, 22:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting strong demand and trading above its 20-day moving average. No specific news was identified.

29 iul. 2026, 19:27 UTC

Royalty Pharma PLC shares are lower today, reflecting a pullback since Tuesday's close amid rising oil prices and inflation concerns.

28 iul. 2026, 23:46 UTC

Royalty Pharma PLC shares are lower in after-market trading, reflecting broader market declines amid concerns over technology sector dynamics.

27 iul. 2026, 16:46 UTC

Royalty Pharma PLC shares are advancing during Monday's session. Broader market gains are supported by a notable decline in oil prices amid easing geopolitical tensions.

24 iul. 2026, 22:21 UTC

In after-market trading, Royalty Pharma PLC is trading higher, nearing the upper end of its one-month range after recovering from an early low.

22 iul. 2026, 19:11 UTC

News

Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

21 iul. 2026, 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

20 iul. 2026, 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Comparație

Modificare preț

Royalty Pharma PLC (Class A) Așteptări

Obiectiv de preț

By TipRanks

12.06% sus

Prognoză pe 12 luni

Medie 65.67 USD 12.06%

Maxim 70 USD

Minim 62 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRoyalty Pharma PLC (Class A) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Royalty Pharma PLC (Class A) - Dist în ultimele 3 luni.

Sentiment

By Acuity

321 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.